Skip to main content
Top
Published in: Endocrine 2/2017

01-02-2017 | Original Article

The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome

Authors: Valentina Guarnotta, Marco C. Amato, Rosario Pivonello, Giorgio Arnaldi, Alessandro Ciresi, Laura Trementino, Roberto Citarrella, Davide Iacuaniello, Grazia Michetti, Chiara Simeoli, Annamaria Colao, Carla Giordano

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

Cushing syndrome (CS) is characterized by increased morbidity and mortality compared to the general population. However, there are patients who have more clinical aggressive forms than others. Aim of the study is to evaluate whether the degree of hypercortisolism, defined by the number of times urinary free cortisol (UFC) levels exceed the upper limit of the normal range (ULN), is related to the worsening of phenotypic features, as well as metabolic and cardiovascular parameters, in a cohort of CS patients. A cross-sectional study was conducted on 192 patients with active CS, consecutively presenting at the outpatients’ clinic of the University Hospitals of Ancona, Naples, and Palermo. Patients were grouped into mild (UFC not exceeding twice the ULN), moderate (2–5 times the ULN), and severe (more than 5 times the ULN) hypercortisolism. Thirty-seven patients (19.3 %) had mild, 115 (59.8 %) moderate, and 40 (20.9 %) severe hypercortisolism. A significant trend of increase among the three groups was demonstrated for 8-, 16-, and 24-h serum cortisol levels (p < 0.001) and serum cortisol after low dose of dexamethasone suppression test (p = 0.001). No significant trend of increase was found regarding phenotype and comorbidities. The degree of hypercortisolism by itself does not appear to be a sufficient parameter to express the severity of CS. Therefore, estimating the severity of CS according to biochemical parameters remains a challenge, while the clinical phenotype and the associated comorbidities might be more useful to assessing the severity of the CS.
Literature
1.
go back to reference X. Bertagna, L. Guignat, L. Groussin, J. Bertherat, Cushing’s disease. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 607–623 (2009)CrossRefPubMed X. Bertagna, L. Guignat, L. Groussin, J. Bertherat, Cushing’s disease. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 607–623 (2009)CrossRefPubMed
2.
go back to reference J. Newell-Price, X. Bertagna, A.B. Grossman et al., Cushing’s syndrome. Lancet 367(9522), 1605–1617 (2006)CrossRefPubMed J. Newell-Price, X. Bertagna, A.B. Grossman et al., Cushing’s syndrome. Lancet 367(9522), 1605–1617 (2006)CrossRefPubMed
3.
go back to reference R. Pivonello, M.C. De Martino, M. De Leo, G. Lombardi, A. Colao, Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 37(1), 135–149 (2008)CrossRefPubMed R. Pivonello, M.C. De Martino, M. De Leo, G. Lombardi, A. Colao, Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 37(1), 135–149 (2008)CrossRefPubMed
5.
go back to reference J. Etxabe, J.A. Vazquez, Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin. Endocrinol. (Oxf) 40(4), 479–484 (1994)CrossRef J. Etxabe, J.A. Vazquez, Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin. Endocrinol. (Oxf) 40(4), 479–484 (1994)CrossRef
6.
go back to reference J. Lindholm, S. Juul, J.O. Jørgensen, J. Astrup, P. Bjerre, Rasmussen U. Feldt et al., Incidence and late prognosis of Cushing’s syndrome: a population-based study. J. Clin. Endocrinol. Metab. 86(1), 117–123 (2001)PubMed J. Lindholm, S. Juul, J.O. Jørgensen, J. Astrup, P. Bjerre, Rasmussen U. Feldt et al., Incidence and late prognosis of Cushing’s syndrome: a population-based study. J. Clin. Endocrinol. Metab. 86(1), 117–123 (2001)PubMed
7.
go back to reference G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35(4), 434–448 (2012)CrossRefPubMed G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35(4), 434–448 (2012)CrossRefPubMed
8.
go back to reference R. Pivonello, A. Faggiano, G. Lombardi, A. Colao, The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 34(2), 327–329 (2005)CrossRefPubMed R. Pivonello, A. Faggiano, G. Lombardi, A. Colao, The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 34(2), 327–329 (2005)CrossRefPubMed
9.
go back to reference A. Faggiano, R. Pivonello, S. Spiezia, M.C. De Martino, M. Filippella, C. Di Somma et al., Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88(6), 2527–2533 (2003)CrossRefPubMed A. Faggiano, R. Pivonello, S. Spiezia, M.C. De Martino, M. Filippella, C. Di Somma et al., Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88(6), 2527–2533 (2003)CrossRefPubMed
10.
go back to reference M.C. Amato, V. Guarnotta, C. Giordano, Body composition assessment for the definition of cardiometabolic risk. J. Endocrinol. Invest. 36(7), 537–543 (2013)PubMed M.C. Amato, V. Guarnotta, C. Giordano, Body composition assessment for the definition of cardiometabolic risk. J. Endocrinol. Invest. 36(7), 537–543 (2013)PubMed
11.
go back to reference G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35(4), 434–448 (2012)CrossRefPubMed G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35(4), 434–448 (2012)CrossRefPubMed
12.
go back to reference M.S. Lionakis, D.P. Kontoyiannis, Glucocorticoids and invasive fungal infections. Lancet 362(9398), 1828–1838 (2003)CrossRefPubMed M.S. Lionakis, D.P. Kontoyiannis, Glucocorticoids and invasive fungal infections. Lancet 362(9398), 1828–1838 (2003)CrossRefPubMed
13.
go back to reference D. Graversen, P. Vestergaard, K. Stochholm, C.H. Gravholt, J.O. Jørgensen, Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur. J. Intern. Med. 23(3), 278–282 (2012)CrossRefPubMed D. Graversen, P. Vestergaard, K. Stochholm, C.H. Gravholt, J.O. Jørgensen, Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur. J. Intern. Med. 23(3), 278–282 (2012)CrossRefPubMed
14.
go back to reference R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96(3), 632–642 (2011)CrossRefPubMed R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96(3), 632–642 (2011)CrossRefPubMed
15.
go back to reference Z.K. Hassan-Smith, M. Sherlock, R.C. Reulen, W. Arlt, J. Ayuk, A.A. Toogood, M.S. Cooper, A.P. Johnson, P.M. Stewart, Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J. Clin. Endocrinol. Metab. 97(4), 1194–1201 (2012)CrossRefPubMed Z.K. Hassan-Smith, M. Sherlock, R.C. Reulen, W. Arlt, J. Ayuk, A.A. Toogood, M.S. Cooper, A.P. Johnson, P.M. Stewart, Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J. Clin. Endocrinol. Metab. 97(4), 1194–1201 (2012)CrossRefPubMed
16.
go back to reference G. Ntali, A. Asimakopoulou, T. Siamatras, J. Komninos, D. Vassiliadi, M. Tzanela, S. Tsagarakis, A.B. Grossman, J.A. Wass, N. Karavitaki, Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur. J. Endocrinol. 169(5), 715–723 (2013)CrossRefPubMed G. Ntali, A. Asimakopoulou, T. Siamatras, J. Komninos, D. Vassiliadi, M. Tzanela, S. Tsagarakis, A.B. Grossman, J.A. Wass, N. Karavitaki, Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur. J. Endocrinol. 169(5), 715–723 (2013)CrossRefPubMed
17.
go back to reference J.R. Lindsay, T. Nansel, S. Baid, J. Gumowski, L.K. Nieman, Longterm impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab. 91(2), 447–453 (2006)CrossRefPubMed J.R. Lindsay, T. Nansel, S. Baid, J. Gumowski, L.K. Nieman, Longterm impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab. 91(2), 447–453 (2006)CrossRefPubMed
18.
go back to reference L. Trementino, G. Apolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur. J. Endocrinol. 166(1), 35–42 (2012)CrossRefPubMed L. Trementino, G. Apolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur. J. Endocrinol. 166(1), 35–42 (2012)CrossRefPubMed
19.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100(8), 2807–2831 (2015)CrossRefPubMedPubMedCentral L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100(8), 2807–2831 (2015)CrossRefPubMedPubMedCentral
20.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008)CrossRefPubMedPubMedCentral L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008)CrossRefPubMedPubMedCentral
21.
go back to reference A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, Pasireotide B2305 Study Group, A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012)CrossRefPubMed A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, Pasireotide B2305 Study Group, A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012)CrossRefPubMed
22.
go back to reference S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, K. Sen, L.R. Salgado, A. Colao, B.M. Biller, High variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin. Endocrinol. (Oxf). 80(2), 261–269 (2014)CrossRefPubMed S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, K. Sen, L.R. Salgado, A. Colao, B.M. Biller, High variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin. Endocrinol. (Oxf). 80(2), 261–269 (2014)CrossRefPubMed
23.
go back to reference J.A. Withworth, World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 21(11), 1983–1992 (2003)CrossRef J.A. Withworth, World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 21(11), 1983–1992 (2003)CrossRef
24.
go back to reference D. Matthews, J. Hosker, A. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28(7), 412–419 (1985)CrossRefPubMed D. Matthews, J. Hosker, A. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28(7), 412–419 (1985)CrossRefPubMed
25.
go back to reference M. Matsuda, R. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9), 1462–1470 (1999)CrossRefPubMed M. Matsuda, R. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9), 1462–1470 (1999)CrossRefPubMed
26.
go back to reference K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32(2), 335–341 (2009)CrossRefPubMedPubMedCentral K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32(2), 335–341 (2009)CrossRefPubMedPubMedCentral
27.
go back to reference M.C. Amato, C. Giordano, M. Galia, A. Criscimanna, S. Vitabile, M. Midiri, A. Galluzzo, AlkaMesy Study Group, Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4), 920–922 (2010)CrossRefPubMedPubMedCentral M.C. Amato, C. Giordano, M. Galia, A. Criscimanna, S. Vitabile, M. Midiri, A. Galluzzo, AlkaMesy Study Group, Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4), 920–922 (2010)CrossRefPubMedPubMedCentral
28.
go back to reference Expert Panel on Detection, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001)CrossRef Expert Panel on Detection, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001)CrossRef
29.
go back to reference M.N. Starkman, B. Giordani, S. Berent, M.A. Schork, DE Schteingart, Elevated cortisol levels in Cushing’s disease are associated with cognitive decrements. Psychosomat. Med. 63(6), 985 (2001)CrossRef M.N. Starkman, B. Giordani, S. Berent, M.A. Schork, DE Schteingart, Elevated cortisol levels in Cushing’s disease are associated with cognitive decrements. Psychosomat. Med. 63(6), 985 (2001)CrossRef
30.
go back to reference N. Sonino, G.A. Fava, A.R. Raffi, M. Boscaro, F. Fallo, Clinical correlates of major depression in Cushing’s disease. Psychopathology 31(6), 302–306 (1998)CrossRefPubMed N. Sonino, G.A. Fava, A.R. Raffi, M. Boscaro, F. Fallo, Clinical correlates of major depression in Cushing’s disease. Psychopathology 31(6), 302–306 (1998)CrossRefPubMed
31.
go back to reference R.C. Bakker, P.R. Gallas, J.A. Romijn, W.M. Wiersinga, Cushing’s syndrome complicated by multiple opportunistic infections. J. Endocrinol. Invest. 21(5), 329–333 (1998)CrossRefPubMed R.C. Bakker, P.R. Gallas, J.A. Romijn, W.M. Wiersinga, Cushing’s syndrome complicated by multiple opportunistic infections. J. Endocrinol. Invest. 21(5), 329–333 (1998)CrossRefPubMed
32.
go back to reference T. Reinehr, A. Kulle, B. Wolters, C. Knop, N. Lass, M. Welzel, P.M. Holterhus, Relationships between 24-hour urinary free cortisol concentrations and metabolic syndrome in obese children. J. Clin. Endocrinol. Metab. 99(7), 2391–2399 (2014)CrossRefPubMed T. Reinehr, A. Kulle, B. Wolters, C. Knop, N. Lass, M. Welzel, P.M. Holterhus, Relationships between 24-hour urinary free cortisol concentrations and metabolic syndrome in obese children. J. Clin. Endocrinol. Metab. 99(7), 2391–2399 (2014)CrossRefPubMed
33.
go back to reference N. Sonino, M. Boscaro, F. Fallo, G.A. Fava, A clinical index for rating severity in Cushing’s syndrome. Psychother. Psychosom. 69(4), 216–220 (2000)CrossRefPubMed N. Sonino, M. Boscaro, F. Fallo, G.A. Fava, A clinical index for rating severity in Cushing’s syndrome. Psychother. Psychosom. 69(4), 216–220 (2000)CrossRefPubMed
34.
go back to reference J.G. Rosmalen, I.P. Kema, S. Wüst, C. van der Ley, S.T. Visser, H. Snieder, S.J. Bakker, 24 h urinary free cortisol in large-scale epidemiological studies: short-term and long-term stability and sources of variability. Psychoneuroendocrinology 47, 10–16 (2014)CrossRefPubMed J.G. Rosmalen, I.P. Kema, S. Wüst, C. van der Ley, S.T. Visser, H. Snieder, S.J. Bakker, 24 h urinary free cortisol in large-scale epidemiological studies: short-term and long-term stability and sources of variability. Psychoneuroendocrinology 47, 10–16 (2014)CrossRefPubMed
35.
go back to reference T. Remer, C. Maser-Gluth, S.A. Wudy, Glucocorticoid measurements in health and disease metabolic implications and the potential of 24-h urine analyses. Mini Rev. Med. Chem. 8(2), 153–170 (2008)CrossRefPubMed T. Remer, C. Maser-Gluth, S.A. Wudy, Glucocorticoid measurements in health and disease metabolic implications and the potential of 24-h urine analyses. Mini Rev. Med. Chem. 8(2), 153–170 (2008)CrossRefPubMed
36.
go back to reference M.M. Kushnir, A.L. Rockwood, G.J. Nelson, A.H. Terry, A.W. Meikle, Liquid chromatography tandem mass spectrometry analysis of urinary free cortisol. Clin. Chem. 49(6), 965–967 (2003)CrossRefPubMed M.M. Kushnir, A.L. Rockwood, G.J. Nelson, A.H. Terry, A.W. Meikle, Liquid chromatography tandem mass spectrometry analysis of urinary free cortisol. Clin. Chem. 49(6), 965–967 (2003)CrossRefPubMed
37.
go back to reference M. Fenske, Urinary free cortisol and cortisone excretion in healthy individuals: influence of water loading. Steroids 71(11–12), 1014–1018 (2006)CrossRefPubMed M. Fenske, Urinary free cortisol and cortisone excretion in healthy individuals: influence of water loading. Steroids 71(11–12), 1014–1018 (2006)CrossRefPubMed
38.
go back to reference K.C.A. Chan, L.C.W. Lit, E.L.K. Law, M.H.L. Tai, C.U. Yung, M.H.M. Chan, C.W.K. Lam, Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin. Chem. 50(4), 757–759 (2004)CrossRefPubMed K.C.A. Chan, L.C.W. Lit, E.L.K. Law, M.H.L. Tai, C.U. Yung, M.H.M. Chan, C.W.K. Lam, Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin. Chem. 50(4), 757–759 (2004)CrossRefPubMed
39.
go back to reference P.C. Elias, E.Z. Martinez, B.F. Barone, L.M. Mermejo, M. Castro, A.C. Moreira, Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 99(6), 2045–2051 (2014)CrossRefPubMed P.C. Elias, E.Z. Martinez, B.F. Barone, L.M. Mermejo, M. Castro, A.C. Moreira, Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 99(6), 2045–2051 (2014)CrossRefPubMed
40.
go back to reference P. Putignano, P. Toja, A. Dubini, F.P. Giraldi, S.M. Corsello, F. Cavagnini, Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J. Clin. Endocrinol. Metab. 88(9), 4153–4157 (2003)CrossRefPubMed P. Putignano, P. Toja, A. Dubini, F.P. Giraldi, S.M. Corsello, F. Cavagnini, Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J. Clin. Endocrinol. Metab. 88(9), 4153–4157 (2003)CrossRefPubMed
41.
go back to reference C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170(2), 311–319 (2013)CrossRefPubMed C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170(2), 311–319 (2013)CrossRefPubMed
42.
go back to reference A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella et al., Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84(8), 2664–2672 (1999)PubMed A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella et al., Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84(8), 2664–2672 (1999)PubMed
43.
go back to reference M. Zilio, L. Mazzai, M.T. Sartori, M. Barbot, F. Ceccato, V. Daidone, A. Casonato, G. Saggiorato, F. Noventa, L. Trementino, P. Prandoni, M. Boscaro, G. Arnaldi, C. Scaroni. A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine 26, 1–11 (2015) M. Zilio, L. Mazzai, M.T. Sartori, M. Barbot, F. Ceccato, V. Daidone, A. Casonato, G. Saggiorato, F. Noventa, L. Trementino, P. Prandoni, M. Boscaro, G. Arnaldi, C. Scaroni. A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine 26, 1–11 (2015)
44.
go back to reference N.J. Sarlis, S.J. Chanock, L.K. Nieman, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J. Clin. Endocrinol. Metab. 85(1), 42–47 (2000)PubMed N.J. Sarlis, S.J. Chanock, L.K. Nieman, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J. Clin. Endocrinol. Metab. 85(1), 42–47 (2000)PubMed
45.
go back to reference S. Takagi, A. Tanabe, M. Tsuiki, M. Naruse, K. Takano, Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing’s syndrome. Endocr. J. 56(8), 1009–1018 (2009)CrossRefPubMed S. Takagi, A. Tanabe, M. Tsuiki, M. Naruse, K. Takano, Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing’s syndrome. Endocr. J. 56(8), 1009–1018 (2009)CrossRefPubMed
46.
go back to reference I. Akaza, T. Yoshimoto, K. Tsuchiya, Y. Hirata, Endothelial dysfunction associated with hypercortisolism is reversible in Cushing’s syndrome. Endocr. J. 57(3), 245–252 (2010)CrossRefPubMed I. Akaza, T. Yoshimoto, K. Tsuchiya, Y. Hirata, Endothelial dysfunction associated with hypercortisolism is reversible in Cushing’s syndrome. Endocr. J. 57(3), 245–252 (2010)CrossRefPubMed
47.
go back to reference F. Fallo, G. Famoso, D. Capizzi, N. Sonino, F. Dassie, P. Maffei, C. Martini, A. Paoletta, S. Iliceto, F. Tona, Coronary microvascular function in patients with Cushing’s syndrome. Endocrine 43(1), 206–213 (2013)CrossRefPubMed F. Fallo, G. Famoso, D. Capizzi, N. Sonino, F. Dassie, P. Maffei, C. Martini, A. Paoletta, S. Iliceto, F. Tona, Coronary microvascular function in patients with Cushing’s syndrome. Endocrine 43(1), 206–213 (2013)CrossRefPubMed
48.
go back to reference A. Gungunes, M. Sahin, T. Demirci, B. Ucan, E. Cakir, M.S. Arslan, I.O. Unsal, B. Karbek, M. Calıskan, M. Ozbek, E. Cakal, T. Delibasi, Cushing’s syndrome in type 2 diabetes patients with poor glycemic control. Endocrine 47(3), 895–900 (2014)CrossRefPubMed A. Gungunes, M. Sahin, T. Demirci, B. Ucan, E. Cakir, M.S. Arslan, I.O. Unsal, B. Karbek, M. Calıskan, M. Ozbek, E. Cakal, T. Delibasi, Cushing’s syndrome in type 2 diabetes patients with poor glycemic control. Endocrine 47(3), 895–900 (2014)CrossRefPubMed
49.
go back to reference P.M. Toja, G. Branzi, F. Ciambellotti, P. Radaelli, M. De Martin, L.M. Lonati, M. Scacchi, G. Parati, F. Cavagnini, F.P. Giraldi, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin. Endocrinol. (Oxf). 76(3), 332–338 (2012)CrossRefPubMed P.M. Toja, G. Branzi, F. Ciambellotti, P. Radaelli, M. De Martin, L.M. Lonati, M. Scacchi, G. Parati, F. Cavagnini, F.P. Giraldi, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin. Endocrinol. (Oxf). 76(3), 332–338 (2012)CrossRefPubMed
50.
go back to reference M.J. Barahona, E. Resmini, D. Viladés, G. Pons-Lladó, R. Leta, T. Puig, S.M. Webb, Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 98(3), 1093–1099 (2013)CrossRefPubMed M.J. Barahona, E. Resmini, D. Viladés, G. Pons-Lladó, R. Leta, T. Puig, S.M. Webb, Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 98(3), 1093–1099 (2013)CrossRefPubMed
51.
go back to reference L. Manetti, G. Rossi, L. Grasso, V. Raffaelli, I. Scattina, S. Del Sarto, M. Cosottini, A. Iannelli, M. Gasperi, F. Bogazzi, E. Martino, Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. Eur. J. Endocrinol. 168(3), 315–321 (2013)CrossRefPubMed L. Manetti, G. Rossi, L. Grasso, V. Raffaelli, I. Scattina, S. Del Sarto, M. Cosottini, A. Iannelli, M. Gasperi, F. Bogazzi, E. Martino, Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. Eur. J. Endocrinol. 168(3), 315–321 (2013)CrossRefPubMed
52.
go back to reference N. Sonino, G.A. Fava, Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15(5), 361–373 (2001)CrossRefPubMed N. Sonino, G.A. Fava, Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15(5), 361–373 (2001)CrossRefPubMed
53.
go back to reference L.D. Dorn, E.S. Burgess, T.C. Friedman, B. Dubbert, P.W. Gold, G.P. Chrousos, The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J. Clin. Endocrinol. Metab. 82(3), 912–919 (1997)PubMed L.D. Dorn, E.S. Burgess, T.C. Friedman, B. Dubbert, P.W. Gold, G.P. Chrousos, The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J. Clin. Endocrinol. Metab. 82(3), 912–919 (1997)PubMed
54.
go back to reference J.R. Seckl, B.R. Walker, 11b-Hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142(4), 1371–1376 (2001)PubMed J.R. Seckl, B.R. Walker, 11b-Hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142(4), 1371–1376 (2001)PubMed
55.
go back to reference V. Morelli, F. Donadio, C. Eller-Vainicher, V. Cirello, L. Olgiati, C. Savoca, E. Cairoli, A.S. Salcuni, P. Beck-Peccoz, I. Chiodini, Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur. J. Clin. Invest. 40(9), 803–811 (2010)CrossRefPubMed V. Morelli, F. Donadio, C. Eller-Vainicher, V. Cirello, L. Olgiati, C. Savoca, E. Cairoli, A.S. Salcuni, P. Beck-Peccoz, I. Chiodini, Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur. J. Clin. Invest. 40(9), 803–811 (2010)CrossRefPubMed
56.
go back to reference H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, J.S. Flier, A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549), 2166–2170 (2001)CrossRefPubMed H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, J.S. Flier, A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549), 2166–2170 (2001)CrossRefPubMed
57.
go back to reference D.J. Wake, B.R. Walker, 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol. Cell. Endocrinol. 215(1–2), 45–54 (2004)CrossRefPubMed D.J. Wake, B.R. Walker, 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol. Cell. Endocrinol. 215(1–2), 45–54 (2004)CrossRefPubMed
58.
go back to reference N.M. Morton, M.C. Holmes, C. Fievet, B. Staels, A. Tailleux, J.J. Mullins, J.R. Seckl, Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276(44), 41293–41300 (2001)CrossRefPubMed N.M. Morton, M.C. Holmes, C. Fievet, B. Staels, A. Tailleux, J.J. Mullins, J.R. Seckl, Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276(44), 41293–41300 (2001)CrossRefPubMed
Metadata
Title
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome
Authors
Valentina Guarnotta
Marco C. Amato
Rosario Pivonello
Giorgio Arnaldi
Alessandro Ciresi
Laura Trementino
Roberto Citarrella
Davide Iacuaniello
Grazia Michetti
Chiara Simeoli
Annamaria Colao
Carla Giordano
Publication date
01-02-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0914-9

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue